Articles

A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma

Department of Medical Oncology, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA; Moores Cancer Center, UC San Diego, LaJolla, CA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA
Department of Medical Oncology, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA; Moores Cancer Center, UC San Diego, LaJolla, CA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA
Department of Medical Oncology, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA; Moores Cancer Center, UC San Diego, LaJolla, CA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA
Department of Medical Oncology, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA; Moores Cancer Center, UC San Diego, LaJolla, CA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA
Department of Medical Oncology, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA; Moores Cancer Center, UC San Diego, LaJolla, CA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA
Department of Medical Oncology, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA; Moores Cancer Center, UC San Diego, LaJolla, CA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA
Department of Medical Oncology, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA; Moores Cancer Center, UC San Diego, LaJolla, CA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA
Department of Medical Oncology, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA; Moores Cancer Center, UC San Diego, LaJolla, CA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA
Department of Medical Oncology, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA; Moores Cancer Center, UC San Diego, LaJolla, CA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA
Department of Medical Oncology, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA; Moores Cancer Center, UC San Diego, LaJolla, CA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA
Department of Medical Oncology, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA; Moores Cancer Center, UC San Diego, LaJolla, CA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA
Department of Medical Oncology, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA; Moores Cancer Center, UC San Diego, LaJolla, CA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA
Department of Medical Oncology, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA; Moores Cancer Center, UC San Diego, LaJolla, CA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA
Department of Medical Oncology, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA; Moores Cancer Center, UC San Diego, LaJolla, CA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA
Department of Medical Oncology, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA; Moores Cancer Center, UC San Diego, LaJolla, CA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA
Department of Medical Oncology, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA; Moores Cancer Center, UC San Diego, LaJolla, CA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA
Department of Medical Oncology, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA; Moores Cancer Center, UC San Diego, LaJolla, CA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA
Department of Medical Oncology, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA; Moores Cancer Center, UC San Diego, LaJolla, CA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA
Department of Medical Oncology, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA; Moores Cancer Center, UC San Diego, LaJolla, CA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA
Vol. 98 No. 6 (2013): June, 2013 https://doi.org/10.3324/haematol.2013.086207